Scholar Rock (SRRK) News Today

Scholar Rock Holding Corporation (NASDAQ: SRRK) shares have decreased as investors weigh the commercial opportunity from the FDA approval of ISEMBYLD against valuation concerns, profit-taking, and a Barclays downgrade. The approval remains a major positive catalyst, but the stock’s reaction suggests that some of the good news may already be reflected in the valuation.

• Positive Sentiment: The FDA approved ISEMBYLD (apitegromab) for spinal muscular atrophy in children and adults, giving Scholar Rock its first commercial product and making it the first approved therapy designed to directly address SMA-related muscle loss. Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment
• Positive Sentiment: Analysts responded favorably to the approval: UBS called the earlier-than-expected decision a “positive surprise,” while Wedbush reaffirmed its outperform rating and maintained a $64 price target. UBS on Scholar Rock FDA Approval
• Positive Sentiment: A Seeking Alpha analysis reiterated a “Strong Buy” view, citing the approval and potential future ISEMBYLD label expansions as drivers of long-term revenue growth. Scholar Rock Strong Buy Analysis
• Neutral Sentiment: Scholar Rock set ISEMBYLD’s list price at $11,659 per single-use vial, or approximately $310,000 annually. The high price supports substantial revenue potential but could create payer-access and reimbursement scrutiny. Scholar Rock Prices ISEMBYLD
• Negative Sentiment: Barclays downgraded SRRK despite the FDA approval, indicating that the stock’s valuation and the risk of translating approval into commercial sales may limit near-term upside. Barclays Downgrades Scholar Rock
• Negative Sentiment: Shares pulled back after the approval-driven rally, suggesting investors may be taking profits or reassessing the stock after the initial FDA enthusiasm. Although Wall Street raised price targets, the market reaction was weaker than the premarket gain. SRRK Shares Pull Back After FDA Approval